Total Payments
$937,773
2024 Payments
$242,020
Companies
49
Transactions
1,122
Medicare Patients
3,454
Medicare Billing
$247,034
Payment Breakdown by Category
Other$703,080 (75.0%)
Travel$109,326 (11.7%)
Consulting$68,115 (7.3%)
Research$32,822 (3.5%)
Food & Beverage$24,061 (2.6%)
Education$368.73 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $703,080 | 209 | 75.0% |
| Travel and Lodging | $109,326 | 227 | 11.7% |
| Consulting Fee | $68,115 | 32 | 7.3% |
| Unspecified | $32,822 | 9 | 3.5% |
| Food and Beverage | $24,061 | 638 | 2.6% |
| Education | $368.73 | 7 | 0.0% |
Payments by Type
General
$904,951
1,113 transactions
Research
$32,822
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $301,325 | 285 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $294,826 | 274 | $0 (2024) |
| GENZYME CORPORATION | $263,044 | 174 | $0 (2024) |
| Valeant Pharmaceuticals North America LLC | $25,871 | 5 | $0 (2017) |
| Arcutis Biotherapeutics, Inc. | $10,671 | 10 | $0 (2024) |
| Lilly USA, LLC | $8,332 | 34 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $8,076 | 12 | $0 (2023) |
| Celgene Corporation | $6,043 | 6 | $0 (2019) |
| Amryt Pharma Holdings Ltd | $3,900 | 2 | $0 (2022) |
| Incyte Corporation | $3,225 | 21 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $242,020 | 209 | Regeneron Healthcare Solutions, Inc. ($78,693) |
| 2023 | $89,654 | 88 | GENZYME CORPORATION ($39,380) |
| 2022 | $182,207 | 154 | GENZYME CORPORATION ($99,220) |
| 2021 | $87,571 | 87 | GENZYME CORPORATION ($40,581) |
| 2020 | $53,097 | 68 | PFIZER INC. ($26,230) |
| 2019 | $165,319 | 198 | Regeneron Healthcare Solutions, Inc. ($78,988) |
| 2018 | $74,201 | 170 | PFIZER INC. ($70,104) |
| 2017 | $43,705 | 148 | Valeant Pharmaceuticals North America LLC ($25,871) |
All Payment Transactions
1,122 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $590.98 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/17/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $475.96 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/17/2024 | Krystal Biotech Inc | VYJUVEK (Drug) | Food and Beverage | In-kind items and services | $21.34 | General |
| Category: DERMATOLOGY | ||||||
| 12/14/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $212.36 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $107.05 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $9.33 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Arcutis Biotherapeutics, Inc. | Zoryve (Drug) | Food and Beverage | In-kind items and services | $14.63 | General |
| Category: Dermatology | ||||||
| 12/06/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $21.87 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $11.12 | General |
| Category: Immunology | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $367.98 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $361.12 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $43.04 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $29.99 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $14.99 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/26/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,697.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $10,675.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,843.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/21/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $23.97 | General |
| Category: Dermatology | ||||||
| 11/20/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $1,476.60 | General |
| 11/20/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $506.25 | General |
| 11/20/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $231.10 | General |
| 11/20/2024 | Lilly USA, LLC | — | Travel and Lodging | In-kind items and services | $220.51 | General |
| 11/20/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $124.27 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/19/2024 | Incyte Corporation | OPZELURA (Drug) | Food and Beverage | Cash or cash equivalent | $4.51 | General |
| Category: Dermatology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Multicenter, Open Label, Single-Arm Study evaluating the Safety and Pharmacokinetics of Efinaconazole 10 Topical Solution in Subjects with Mild to Severe Onychomycosis of the Toenails | Valeant Pharmaceuticals North America LLC | $25,840 | 2 |
| A Phase 2, Multicenter, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis (CC-10004-PPSO-001) | Celgene Corporation | $4,010 | 1 |
| CC-10004-PPSO-001 - A Phase 2, Multicenter, Open-Label Study to Assess the Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects with Moderate to Severe Plaque Psoriasis | Celgene Corporation | $1,966 | 1 |
| A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants 6 Months to <18 Years of Age With Prurigo Nodularis | SANOFI US SERVICES INC. | $1,006 | 5 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 586 | 1,013 | $174,559 | $42,011 |
| 2022 | 11 | 982 | 1,855 | $287,261 | $72,902 |
| 2021 | 12 | 981 | 1,864 | $282,180 | $75,154 |
| 2020 | 10 | 905 | 1,733 | $220,934 | $56,968 |
Total Patients
3,454
Total Services
6,465
Medicare Billing
$247,034
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 126 | 165 | $51,654 | $13,881 | 26.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 143 | 168 | $37,224 | $9,189 | 24.7% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2023 | 97 | 116 | $22,598 | $4,272 | 18.9% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2023 | 49 | 55 | $16,641 | $3,315 | 19.9% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2023 | 20 | 25 | $12,227 | $3,056 | 25.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 29 | 29 | $11,802 | $2,958 | 25.1% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2023 | 28 | 28 | $9,332 | $2,242 | 24.0% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2023 | 75 | 408 | $7,901 | $1,992 | 25.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 19 | 19 | $5,180 | $1,106 | 21.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 179 | 240 | $75,840 | $20,135 | 26.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 173 | 221 | $49,283 | $13,888 | 28.2% |
| 17000 | Destruction of precancer skin growth, 1 growth | Office | 2022 | 196 | 254 | $49,276 | $10,487 | 21.3% |
| 11102 | Biopsy of related skin growth, first growth | Office | 2022 | 85 | 91 | $27,846 | $6,515 | 23.4% |
| 17110 | Destruction of skin growth, 1-14 growths | Office | 2022 | 58 | 63 | $21,042 | $5,133 | 24.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 40 | 40 | $16,401 | $4,794 | 29.2% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Office | 2022 | 154 | 835 | $15,865 | $4,167 | 26.3% |
| 17004 | Destruction of precancer skin growth, 15 or more growths | Office | 2022 | 24 | 31 | $15,066 | $3,726 | 24.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 39 | 39 | $10,647 | $2,597 | 24.4% |
| 11103 | Biopsy of related skin growth, each additional growth | Office | 2022 | 15 | 21 | $3,255 | $846.38 | 26.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 19 | 20 | $2,740 | $614.74 | 22.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 178 | 244 | $73,625 | $22,607 | 30.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 145 | 180 | $38,454 | $11,387 | 29.6% |
| 17000 | Destruction of skin growth | Office | 2021 | 175 | 234 | $45,195 | $9,307 | 20.6% |
| 11102 | Tangential biopsy of single skin lesion | Office | 2021 | 98 | 115 | $34,812 | $8,557 | 24.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 51 | 51 | $20,717 | $5,880 | 28.4% |
About Dr. Emily Becker, M.D
Dr. Emily Becker, M.D is a Dermatology healthcare provider based in San Antonio, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/22/2008. The National Provider Identifier (NPI) number assigned to this provider is 1265619217.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Emily Becker, M.D has received a total of $937,773 in payments from pharmaceutical and medical device companies, with $242,020 received in 2024. These payments were reported across 1,122 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($703,080).
As a Medicare-enrolled provider, Becker has provided services to 3,454 Medicare beneficiaries, totaling 6,465 services with total Medicare billing of $247,034. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Pediatric Dermatology, Pediatrics
- Location San Antonio, TX
- Active Since 01/22/2008
- Last Updated 07/16/2018
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1265619217
Products in Payments
- DUPIXENT (Biological) $543,545
- EUCRISA (Drug) $184,208
- CIBINQO (Drug) $111,771
- JUBLIA (Drug) $25,842
- DUPIXENT (Drug) $10,921
- Zoryve (Drug) $10,671
- Otezla (Drug) $6,019
- COSENTYX (Biological) $2,602
- VTAMA (Drug) $2,254
- DUPIXENT DUPILUMAB INJECTION (Biological) $935.15
- TALTZ (Drug) $658.92
- OPZELURA (Drug) $534.72
- Cimzia (Drug) $503.66
- Ketodan (Drug) $502.44
- DORYX (Drug) $421.56
- Humira (Biological) $367.94
- Sotyktu (Drug) $318.49
- TREMFYA (Drug) $285.49
- Enbrel (Biological) $276.84
- ADBRY (Biological) $261.17
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in San Antonio
Dr. William Cragun, M.d, M.D
Dermatology — Payments: $1.9M
Dermatology $1.9M
Dr. Mark Lee, M.d, M.D
Dermatology — Payments: $589,973
Dermatology $589,973
Dr. Lindsey Finklea, M.d, M.D
Dermatology — Payments: $265,879
Dermatology $265,879
Steven Davis, Md, MD
Dermatology — Payments: $114,713
Dermatology $114,713
Stephen Miller, M.d. P.a, M.D. P.A
Dermatology — Payments: $89,896
Dermatology $89,896
Dr. Mobolaji Opeola, M.d, M.D
Dermatology — Payments: $66,660
Dermatology $66,660